Australia Federal Court holds CRESTOR patents invalid
- Details
- Category: AstraZeneca
AstraZeneca today announced that the Federal Court of Australia has found three patents protecting CRESTOR (rosuvastatin) to be invalid. These patents - a formulation patent (AU 200051842, with an expiry date in 2020); a second related to the use of rosuvastatin for treating heterozygous familial hypercholesterolemia (AU 2002214165, with an expiry date in 2021); and a third related to the use of rosuvastatin for treating hypercholesterolemia (AU 2000023051, with an expiry date in 2020) - were challenged by Apotex Pty Ltd, Watson Pharma Pty Ltd and Ascent Pharma Pty Ltd.
Bayer: continuing growth momentum
- Details
- Category: Bayer
2012 was a very successful year for the Bayer Group. "We continued to grow dynamically and achieved our targets for the Group. All the subgroups posted gains in sales and earnings before special items," said Bayer CEO Dr. Marijn Dekkers at the Financial News Conference in Leverkusen on Thursday.
Novartis collaboration aims to eliminate rheumatic heart disease (RHD) in Zambia, Africa
- Details
- Category: Novartis
Novartis today announced that it has launched an effort to eliminate rheumatic heart disease in Zambia in collaboration with the Lusaka University Teaching Hospital (UTH), the Ministry of Health in Zambia, the Pan-African Cardiology Society and Massachusetts General Hospital (MGH).
Roche launches new process for accessing clinical trial data
- Details
- Category: Roche
Roche is expanding access to its clinical trial data for third party researchers. Roche will work with an independent body of recognised experts to evaluate and approve requests to access anonymised patient-level data. Roche will support the release of full clinical study reports (CSRs) for all its licensed medicines via regulatory authorities and make available any CSRs that cannot be provided by these authorities upon a researcher’s request.
Bayer's Stivarga® (regorafenib) tablets approved by FDA for treatment of patients with gastrointestinal stromal tumors
- Details
- Category: Bayer
Bayer HealthCare announced that the U.S. Food and Drug Administration (FDA) approved Bayer's Stivarga® (regorafenib) tablets to treat patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.
FDA approves Roche's Kadcyla (trastuzumab emtansine), the first antibody-drug conjugate for treating HER2-positive metastatic breast cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved Kadcyla (trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin (trastuzumab) and a taxane chemotherapy. Kadcyla is the fourth medicine from Roche to receive FDA approval for people with advanced cancers within the past two years.
Abbott to collaborate with Janssen and Pharmacyclics
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced that it will collaborate with Janssen Biotech, Inc. and Pharmacyclics, Inc. to explore the benefits of Abbott's proprietary FISH (fluorescence in situ hybridization) technology for use in developing a molecular companion diagnostic test to identify patients with a genetic subtype of chronic lymphocytic leukemia (CLL), the most common form of adult leukemia.
More Pharma News ...
- New findings from two studies support substantial benefit of Pradaxa®
- UCB announces regulatory filings for Cimzia® (certolizumab pegol)
- Sanofi New Drug Application for lixisenatide accepted for review by FDA
- ViiV Healthcare announces FDA priority review designation for dolutegravir
- Accelerating focus on the patient
- Bristol-Myers Squibb enters a collaboration agreement with Reckitt Benckiser Group plc
- Sanofi delivers solid 2012 results despite patent expirations